News

For Immediate Release

OTTAWA, Canada, September 30, 2015 — Nordion, a standalone business within Sterigenics International, today welcomed the Canadian Nuclear Safety Commission (CNSC) decision to renew the Nuclear Substance Processing Facility Operating License for the company’s Class 1B nuclear substance processing facility in Ottawa, Ontario. The license renewal is for 10 years until 2025.

“We welcome today’s announcement as it follows an extensive and rigorous evaluation of our operations by Canada’s nuclear regulator,” said Scott McIntosh, President, Gamma Technologies and Corporate Services of Nordion. “This is great news for our employees, our customers, and for the healthcare community around the world that rely on Nordion’s products every day and further demonstrates the confidence the CNSC has in our operations.”

Nordion is the leading provider of medical isotopes and gamma technologies used for the prevention, diagnosis and treatment of disease to the benefit of millions of patients around the world. Nordion has been operating its nuclear substance processing facility in Ottawa, Ontario since 1972. The company appeared before the CNSC on August 19, 2015 as part of the standard process when applying for a Nuclear Substance Processing Facility Operating license renewal. This meeting was also the culmination of a process that enabled stakeholders and the general public to submit their comments, concerns, and questions.

“We appreciate the work and dedication of our employees, and the wealth of support we received from our partners, clients, healthcare professionals as well as the broad Ottawa community support throughout this entire process,” said McIntosh. “This license renewal comes at a time when regulators around the world are continually raising the bar around environment, health, and safety standards. We are pleased to be operating in line with the expectations of our regulator and our community.”

In Canada, the CNSC is responsible for regulating the use of nuclear energy and materials to protect the health, safety and security of Canadians and the environment; to implement Canada’s international commitments on the peaceful use of nuclear energy; and to disseminate objective scientific, technical and regulatory information to the public.

Nordion processes radioisotopes for medical and industrial applications and is located in Kanata (Ottawa), Ontario. Agendas, hearing transcripts and information on the hearing process are available at the CNSC website at www.nuclearsafety.gc.ca.

Nordion provides market-leading products used for the prevention, diagnosis and treatment of disease. We are a leading provider of medical isotopes and gamma technologies that benefit the lives of millions of people around the world. Our products are used daily by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Nordion supplies products to approximately 500 customers across more than 40 countries around the globe, and is a standalone business within Sterigenics International LLC, the global leader in outsourced contract sterilization services, gamma technologies and medical isotopes. Find out more about Nordion at www.nordion.com and follow us at twitter.com/NordionInc.